Dynavax to Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on February 20, 2025

Rhea-AI Summary

Dynavax Technologies (Nasdaq: DVAX), a commercial-stage biopharmaceutical company focused on vaccine development, has scheduled its fourth quarter and full year 2024 financial results announcement for February 20, 2025, after U.S. market close. The company will host a conference call and webcast at 4:30 p.m. ET/1:30 p.m. PT on the same day.

Dynavax currently markets two commercial products: HEPLISAV-B vaccine, approved in the U.S., EU, and Great Britain for hepatitis B virus prevention in adults 18 and older, and CpG 1018 adjuvant, used in HEPLISAV-B and various COVID-19 vaccines.

Positive

• Has two commercialized products in major markets (HEPLISAV-B and CpG 1018)
• HEPLISAV-B approved in multiple major markets (US, EU, UK)

Negative

• None.

EMERYVILLE, Calif., Feb. 6, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report fourth quarter and full year 2024 financial results on Thursday, February 20, 2025, after the U.S. financial markets close.

Dynavax will host a conference call and live audio webcast on Thursday, February 20, 2025, at 4:30 p.m. ET/1:30 p.m. PT.

The live audio webcast may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at https://investors.dynavax.com/events-presentations. A replay of the webcast will be available for 30 days following the live event.

To dial into the call, participants will need to register for the call using the caller registration link. It is recommended that participants dial into the conference call or log into the webcast approximately 10 minutes prior to the call.

About Dynavax
Dynavax is a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against infectious diseases. The Company has two commercial products, HEPLISAV-B^® vaccine [Hepatitis B Vaccine (Recombinant), Adjuvanted], which is approved in the U.S., the European Union and Great Britain for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older, and CpG 1018^® adjuvant, currently used in HEPLISAV-B and multiple adjuvanted COVID-19 vaccines. For more information about our marketed products and development pipeline, visit www.dynavax.com.

For Investors/Media:
Paul Cox
pcox@dynavax.com
510-665-0499 

Nicole Arndt
narndt@dynavax.com
510-665-7264

View original content to download multimedia:https://www.prnewswire.com/news-releases/dynavax-to-report-fourth-quarter-and-full-year-2024-financial-results-and-host-conference-call-on-february-20-2025-302370741.html

SOURCE Dynavax Technologies

FAQ

When will Dynavax (DVAX) report Q4 and full year 2024 earnings?

Dynavax will report Q4 and full year 2024 financial results on Thursday, February 20, 2025, after U.S. market close.

What time is Dynavax's (DVAX) Q4 2024 earnings call?

Dynavax's earnings conference call is scheduled for Thursday, February 20, 2025, at 4:30 p.m. ET/1:30 p.m. PT.

What are Dynavax's (DVAX) main commercial products?

Dynavax has two main commercial products: HEPLISAV-B vaccine for hepatitis B prevention and CpG 1018 adjuvant used in various vaccines.

Where is Dynavax's (DVAX) HEPLISAV-B vaccine approved?

HEPLISAV-B is approved in the United States, the European Union, and Great Britain for adults 18 years and older.